Inhibrx (INBX) Surges After Ozekibart Cuts Cancer Progression Risk by 52%
Inhibrx Inc. (NASDAQ:INBX) is a clinical-stage biopharmaceutical company focused on developing a new generation of therapeutic candidates designed…
Browsing Tag